Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir-Reference-Cited by-同舟云学术

Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir

Published:2019-11-12 Issue:2 Volume:48 Page:213-221
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Calza Leonardo^ORCID,Colangeli Vincenzo,Borderi Marco,Bon Isabella,Borioni Aurora,Volpato Francesca,Re Maria Carla,Viale Pierluigi

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s15010-019-01376-5.pdf

Reference25 articles.

1. Demir OM, Candilio L, Fuster D, Muga R, Barbaro G, Colombo A, et al. Cardiovascular disease burden among human immunodeficiency virus-infected individuals. Int J Cardiol. 2018;265:195–203.

2. Sinha A, Feinstein MJ. Coronary artery disease manifestations in HIV: what, how, and why. Can J Cardiol. 2019;35:270–9.

3. Guaraldi G, Oralndo G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.

4. Rao SG, Galaviz KI, Gay HC, Wei J, Armstrong WS, del Rio C, et al. Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2019 Feb 20 [Epub ahead of print].

5. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228–30.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism;Current HIV/AIDS Reports;2024-08-29

2. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial;The Lancet HIV;2024-07

3. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi;BMC Public Health;2024-05-16

4. Effect of the timing of antiretroviral treatment initiation on CD4 count in children and youths living with HIV in North India;International Journal of STD & AIDS;2024-01-12

5. Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study;AIDS Research and Therapy;2024-01-07